Skip to main content
. Author manuscript; available in PMC: 2014 Mar 25.
Published in final edited form as: Clin Trials. 2013 Mar 25;10(3):422–429. doi: 10.1177/1740774513480961

Figure 2.

Figure 2

Probability of stopping due to toxicity for the various scenarios and the three different phase II designs. For the single-arm phase II design, all patients are treated at the RD level; in the 2-arm phase II design, patients are randomized to RD and RD−; in the 3-arm phase II design, patients are randomized to RD, RD+, and RD−: (a) good dose level and (b) best dose level.

RD: phase II RD level; RD+ : dose level immediately above phase II RD level; RD−: dose level immediately below phase II RD level.